UroGen Pharma Ltd.
URGNHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, UroGen Pharma Ltd. focuses on Biotechnology services and products. UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. The $1.69B market capitalization puts URGN squarely in small-cap range for its industry. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Market Cap
$1.69B
Beta
1.58
P/E (TTM)
—
P/E (Fwd)
13.33
EPS (TTM)
$-1.97
EPS (Fwd)
$2.59
ROE
—
ROA
-18.1%
Cash
$108.0M
Total Debt
$196.1M
Free CF
-$107.0M
52W Change
65.4%
Annual Financials
Cash vs Debt
Where URGN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, URGN finished 0.03% above its 150-day moving average ($34.14) and 11.09% above its 200-day moving average ($30.74). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is URGN overbought or oversold?
At the October 20, 2026 close, URGN's RSI(14) was 27.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $108.0M in cash, though total debt stands at $196.1M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$107.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $64.4M (2022) to $109.8M (2025), reflecting a 71% increase over the period.
UroGen Pharma Ltd.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing URGN.